Article
Vancomycin Hydrochloride for Injection Product Launches
The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.
Officials with Xellia Pharmaceuticals (‘Xellia’) announced they have launched Vancomycin Hydrochloride for Injection, USP within the United States market.
The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.
“Today marks an important milestone for our US market strategy and represents a significant step forward in the company's evolution as we bring the first product to the US market under the Xellia brand,” Carl-Aake Carlsson, Xellia’s CEO, said in a prepared statement about the launch.
Full prescribing information for Vancomycin Hydrochloride for Injection, USP can be found at www.xellia.com/us.
FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis in Adults and Children
